Sentence examples for discontinuation average from inspiring English sources

A total of 69 of the 165 (41.8%) patients experienced a decrease in SCr prior to discontinuation (average decrease was 1.04±1.77) and 76 (46.0%) of the patients experienced an increase (average increase was 1.86±0.87) and 20 (12.1%) patients experienced no change from baseline prior to discontinuation.

Overall, adverse event discontinuations averaged 14% and lack of efficacy discontinuations averaged 10% in the cohort studies (Table 1).

Abatacept had an average discontinuation rate due to insufficient clinical efficacy.

Treatment switching is common among patients with schizophrenia and was incorporated into this Markov cohort analysis through the use of a composite health state, consisting of average discontinuation rates, costs, and outcomes of noncomparator agents.

Patients were more likely to stay on fixed-dose combinations longer than monotherapy, as mean time to therapy discontinuation was, on average, two and a half months longer for fixed-dose combinations than for monotherapy.

In the scenario without sexual disinhibition occurring, the rate of PrEP discontinuation (inverse of the average duration of PrEP use) was the strongest determinant overall of reduction in infections and its effect persisted over time (PRCC ranged from −0.94 at year 5 to −0.97 at year 20).

The average after discontinuation of medicine treatment was in the period of 4.1 ± 2.6 months (0 12 months), at the end of the first month of CsA discontinuation no recurrence was observed in eight eyes however three months after the discontinuation of medication recurrence was observed in two eyes which had CsA medication for 7 and 8 months respectively (Table 1).

The composite therapy was operationalized by averaging the discontinuation rates (transition probabilities), costs, and outcomes of the other comparator AAPs among which the patient might possibly switch (eg, if a patient initiates treatment with lurasidone, then the composite would reflect the average of aripiprazole, olanzapine, quetiapine extended-release, risperidone, and ziprasidone).

The decline in infections was also very sensitive to the PrEP discontinuation rate (inverse of the average duration of PrEP use) and the level of coverage.

The rate of discontinuation was somewhat higher than average among patients with prior cardiovascular disease or older age, but was similar for other major groupings.

The average time until discontinuation was 156 days for exenatide-treated patients and 111 days for glargine-treated patients (p < 0.0001).